International Isotopes Inc (INIS) (OTCQB:INIS), a US supplier of generic sodium iodide I-131 radio-pharmaceutical drug products for hyperthyroidism and thyroid cancer, announced on Wednesday that it has filed a Certificate of Amendment in the State of Texas to change its legal name to Radnostix Inc, effective immediately.
The company is planning to rebrand all its operations under the Radnostix name.
INIS was established in 1995 with a focus on irradiation and manufacturing of industrial radioisotope products. Its focus has evolved over the years, and the name change reflects the company's expanding product segments and evolving strategic focus on radioisotopes and theranostics products.
The INIS branding will be maintained in segments focused on high energy sources, bulk radioisotopes, and stable isotopes.
For the time being, the company's common stock will continue to trade under its current ticker symbol 'INIS' on the OTCQB marketplace.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream